Pharma Sector

Indian benchmark indices ended higher on September 10, 2026, snapping a three-session losing streak. Nifty and Sensex gained 0.20% and 0.19%, respectively, led by banking and financial stocks, while crude oil above $100, rupee weakness and pressure in auto and metal stocks kept gains limited.

Indian markets ended lower on Thursday, with the Nifty 50 falling 41 points and the Sensex declining 417 points amid sharp expiry-day volatility. Banking stocks gained after the RBI reported $136.38 billion in foreign currency inflows, while Solar Industries rallied on acquisition buzz.

Indian benchmark indices ended marginally lower on September 1, 2026, extending losses for a second consecutive session. The Nifty 50 fell 0.10% to 24,055.80, while the Sensex declined 0.02% to 76,944.28. Renewed US-Iran tensions and Brent crude crossing $91 a barrel pressured banking, auto, realty and pharma stocks, while gains in ITC, IT and telecom counters capped the downside.

Symbiotec Pharmalab shares made a flat debut at ₹988 on the NSE, matching the IPO issue price. The stock later rallied nearly 11% to ₹1,092.40, after touching an intraday high of ₹1,098. The IPO was subscribed 71.26 times, with QIBs leading demand at 172.03 times.

The MSCI index reshuffle takes effect on September 1, bringing Laurus Labs, Lenskart, Adani Energy Solutions and Groww into focus. Here’s what the changes mean, why global funds may buy or sell these stocks, how Reliance Industries is affected, and why the new Closing Auction Session could lead to higher volatility.

Symbiotec Pharmalab IPO GMP stands at ₹340 on August 26, 2026. The IPO is subscribed 3.82x overall, with NII subscription at 7.88x.

Symbiotec Pharmalab IPO GMP stands at ₹340 on August 26, 2026. The IPO is subscribed 3.82x overall, with NII subscription at 7.88x.

Symbiotech Pharmalab IPO has attracted 1.71x subscription as of August 25, 2026, while its GMP stands at ₹350. The latest grey market trend indicates an estimated listing price of ₹1,338, or a 35.43% premium over the ₹988 issue price.

Symbiotec Pharmalab IPO opened for subscription on August 24, 2026. The latest GMP stands at ₹409 against the IPO price of ₹988, indicating an estimated listing price of ₹1,397 and a potential premium of 41.40%.

The renewed US-Iran conflict and uncertainty around the Strait of Hormuz are putting oil prices and global markets under pressure. Here’s how prolonged disruption could affect crude, inflation and stock markets in India, the US and Europe.